The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
- Resource Type
- Source
- Haematologica. 102:e400-e403
- Subject
CD20 biology Chronic lymphocytic leukemia Hematology medicine.disease In vitro 03 medical and health sciences Leukemia chemistry.chemical_compound 0302 clinical medicine chemistry Antigen immune system diseases hemic and lymphatic diseases 030220 oncology & carcinogenesis Ibrutinib Immunology biology.protein medicine Cancer research Bruton's tyrosine kinase Acalabrutinib 030215 immunology - Language
- ISSN
- 1592-8721
0390-6078